medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2022, Number 2

<< Back Next >>

Rev Mex Urol 2022; 82 (2)

Checkpoint inhibition: the current treatment of renal cell carcinoma

García-Robledo JE, García-Perdomo HA

Language: Spanish
References: 50
Page:
PDF size: 686.63 Kb.


ABSTRACT

Immune surveillance is one of the most important hallmarks of cancer. In the last decade many advancements in cancer treatment have been developed, much of them are related to the use of the immune system. Renal Cell Carcinoma is the most frequent type of kidney cancer followed by urothelial carcinoma. For years, treatment of Renal Cell Carcinoma has been conflictive as these tumors do not respond well to chemotherapy and have shown to be susceptible to immunotherapies as interferon and interleukin 2. The discovery of the immune checkpoints and their possible roles in cancer treatment led to the synthesis of novel drugs that can target and inhibit the interaction of certain molecules that are important for immunologic homeostasis. In this concise review, we summarize the evidence related with immune checkpoint inhibition for the treatment of renal cell carcinoma, especially for metastatic renal cell carcinoma.


REFERENCES

  1. Rübben A, Araujo A. Cancer heterogeneity:converting a limitation into a source of biologicinformation. Journal of Translational Medicine.2017;15(1):190. doi: https://doi.org/10.1186/s12967-017-1290-9

  2. Hanahan D, Weinberg RA. Hallmarks of Cancer:The Next Generation. Cell. 2011;144(5):646–74.doi: https://doi.org/10.1016/j.cell.2011.02.013

  3. Falzone L, Salomone S, Libra M. Evolution ofCancer Pharmacological Treatments at the Turnof the Third Millennium. Front Pharmacol.2018;9:1300. doi: https://doi.org/10.3389/fphar.2018.01300

  4. Lu M, Su Y. Immunotherapy in non-small celllung cancer: The past, the present, and thefuture. Thoracic Cancer. 2019;10(4):585–6. doi:https://doi.org/10.1111/1759-7714.13012

  5. Domingues B, Lopes JM, Soares P, Pópulo H.Melanoma treatment in review. ITT. 2018;7:35–49. doi: https://doi.org/10.2147/ITT.S134842

  6. Lugowska I, Teterycz P, Rutkowski P.Immunotherapy of melanoma. Contemp Oncol(Pozn). 2018;22(1A):61–7. doi: https://doi.org/10.5114/wo.2018.73889

  7. Tung I, Sahu A. Immune Checkpoint Inhibitorin First-Line Treatment of Metastatic Renal CellCarcinoma: A Review of Current Evidence andFuture Directions. Front Oncol. 2021;11:707214.doi: 10.3389/fonc.2021.707214

  8. Pan R-Y, Chung W-H, Chu M-T, Chen S-J,Chen H-C, Zheng L, et al. Recent Developmentand Clinical Application of Cancer Vaccine:Targeting Neoantigens. Journal of ImmunologyResearch. 2018;e4325874. doi: https://doi.org/10.1155/2018/4325874

  9. Ribatti D. The concept of immune surveillanceagainst tumors: The first theories. Oncotarget.2016;8(4):7175–80. doi: https://doi.org/10.18632/oncotarget.12739

  10. Nowell PC. The clonal evolution of tumor cellpopulations. Science. 1976;194(4260):23–8.doi: https://www.science.org/doi/10.1126/science.959840

  11. Paluch C, Santos AM, Anzilotti C, Cornall RJ,Davis SJ. Immune Checkpoints as TherapeuticTargets in Autoimmunity. Frontiers inImmunology. 2018;9. doi: https://doi.org/10.3389/fimmu.2018.02306

  12. Siegel RL, Miller KD, Jemal A. Cancer statistics,2018. CA Cancer J Clin. 2018;68(1):7–30. doi:https://doi.org/10.3322/caac.21442

  13. Protzel C, Maruschke M, Hakenberg OW.Epidemiology, Aetiology, and Pathogenesisof Renal Cell Carcinoma. European UrologySupplements. 2012;11(3):52–9. doi: https://doi.org/10.1016/j.eursup.2012.05.002

  14. Pal SK, Ghate SR, Li N, Swallow E, PeeplesM, Zichlin ML, et al. Real-World SurvivalOutcomes and Prognostic Factors AmongPatients Receiving First Targeted Therapyfor Advanced Renal Cell Carcinoma: A SEERMedicareDatabase Analysis. Clin GenitourinCancer. 2017;15(4):e573–82. doi: https://doi.org/10.1016/j.clgc.2016.12.00515

  15. Motzer RJ, Bander NH, Nanus DM. Renal-cellcarcinoma. N Engl J Med. 1996;335(12):865–75. doi:https://doi.org/10.1056/nejm199609193351207

  16. Nazha S, Tanguay S, Kapoor A, Jewett M,Kollmannsberger C, Wood L, et al. Use ofTargeted Therapy in Patients with MetastaticRenal Cell Carcinoma: Clinical and EconomicImpact in a Canadian Real-Life Setting. CurrentOncology. 2018;25(6):576–84. doi: https://doi.org/10.3747/co.25.4103

  17. Patard J-J, Kim HL, Lam JS, Dorey FJ, PantuckAJ, Zisman A, et al. Use of the Universityof California Los Angeles Integrated StagingSystem to Predict Survival in Renal CellCarcinoma: An International Multicenter Study.JCO. 2004;22(16):3316–22. doi: https://doi.org/10.1200/jco.2004.09.104

  18. Ridge CA, Pua BB, Madoff DC. Epidemiologyand Staging of Renal Cell Carcinoma. Seminintervent Radiol. 2014;31(01):003–8. doi:https://doi.org/10.1055/s-0033-1363837

  19. Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cellcarcinoma: ESMO Clinical Practice Guidelinesfor diagnosis, treatment and follow-up†. Annalsof Oncology. 2019;30(5):706–20. doi: https://doi.org/10.1093/annonc/mdz056

  20. Freed SZ, Halperin JP, Gordon M.Idiopathic Regression of Metastases fromRenal Cell Carcinoma. Journal of Urology.1977;118(4):538–42. doi: https://doi.org/10.1016/S0022-5347(17)58099-4

  21. Jilaveanu LB, Shuch B, Zito CR, Parisi F,Barr M, Kluger Y, et al. PD-L1 Expression inClear Cell Renal Cell Carcinoma: An Analysisof Nephrectomy and Sites of Metastases. JCancer. 2014;5(3):166–72. doi: https://doi.org/10.7150/jca.8167

  22. Rosenberg SA, Lotze MT, Muul LM, Leitman S,Chang AE, Ettinghausen SE, et al. Observationson the Systemic Administration of AutologousLymphokine-Activated Killer Cells andRecombinant Interleukin-2 to Patients withMetastatic Cancer. New England Journal ofMedicine. 1985;313(23):1485–92. doi: https://doi.org/10.1056/nejm198512053132327

  23. Coppin C, Porzsolt F, Autenrieth M, KumpfJ, Coldman A, Wilt T. Immunotherapy foradvanced renal cell cancer. Cochrane Databaseof Systematic Reviews. 2004;(3). doi: https://doi.org/10.1002/14651858.CD001425.pub2

  24. Thompson RH, Gillett MD, Cheville JC,Lohse CM, Dong H, Webster WS, et al.Costimulatory B7-H1 in renal cell carcinomapatients: Indicator of tumor aggressiveness andpotential therapeutic target. Proc Natl Acad SciU S A. 2004;101(49):17174–9. doi: https://doi.org/10.1073/pnas.0406351101

  25. Zong Sheng Guo. The 2018 Nobel Prize inmedicine goes to cancer immunotherapy. BMCCancer. 2018 Nov 12;18(1):1086. doi: https://doi.org/10.1186/s12885-018-5020-3

  26. Waterhouse P, Penninger JM, Timms E,Wakeham A, Shahinian A, Lee KP, et al.Lymphoproliferative disorders with earlylethality in mice deficient in Ctla-4. Science.1995;270(5238):985–8. doi: https://doi.org/10.1126/science.270.5238.985

  27. Tivol EA, Borriello F, Schweitzer AN, LynchWP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation andfatal multiorgan tissue destruction, revealinga critical negative regulatory role of CTLA-4.Immunity. 1995;3(5):541–7. doi: https://doi.org/10.1016/1074-7613(95)90125-6

  28. Klocke K, Sakaguchi S, Holmdahl R, Wing K.Induction of autoimmune disease by deletionof CTLA-4 in mice in adulthood. Proceedingsof the National Academy of Sciences.2016;113(17):E2383–92. doi: https://doi.org/10.1073/pnas.1603892113

  29. Mitsuiki N, Schwab C, Grimbacher B. Whatdid we learn from CTLA-4 insufficiencyon the human immune system? ImmunolRev. 2019;287(1):33–49. doi: https://doi.org/10.1111/imr.12721

  30. Iwai Y, Ishida M, Tanaka Y, Okazaki T, HonjoT, Minato N. Involvement of PD-L1 on tumorcells in the escape from host immune systemand tumor immunotherapy by PD-L1 blockade.Proceedings of the National Academy ofSciences. 2002;99(19):12293–7. doi: https://doi.org/10.1073/pnas.192461099

  31. Nishimura H, Minato N, Nakano T, Honjo T.Immunological studies on PD-1 deficient mice:implication of PD-1 as a negative regulator for Bcell responses. Int Immunol. 1998;10(10):1563–72. doi: 10.1093/intimm/10.10.1563

  32. Vaddepally RK, Kharel P, Pandey R, Garje R,Chandra AB. Review of Indications of FDAApprovedImmune Checkpoint Inhibitors perNCCN Guidelines with the Level of Evidence.Cancers. 2020;12(3):738. doi: https://doi.org/10.3390/cancers12030738

  33. Krabbe L-M, Bagrodia A, Margulis V, Wood CG.Surgical Management of Renal Cell Carcinoma.Semin intervent Radiol. 2014;31(01):027–32.doi: https://doi.org/10.1055/s-0033-1363840

  34. Posadas EM, Limvorasak S, Figlin RA. Targetedtherapies for renal cell carcinoma. Nat RevNephrol. 2017 Aug;13(8):496–511. doi: https://doi.org/10.1038/nrneph.2017.82

  35. Tran J, Ornstein MC. Clinical Review on theManagement of Metastatic Renal Cell Carcinoma.JCO Oncology Practice. 2022;18(3):187–96.doi: https://doi.org/10.1200/op.21.00419

  36. Powles T, Albiges L, Staehler M, BensalahK, Dabestani S, Giles RH, et al. UpdatedEuropean Association of Urology Guidelines:Recommendations for the Treatment ofFirst-line Metastatic Clear Cell Renal Cancer.European Urology. 2018 1;73(3):311–5. doi:https://doi.org/10.1016/j.eururo.2017.11.016

  37. Cella D, Beaumont JL. Pazopanib in thetreatment of advanced renal cell carcinoma.Ther Adv Urol. 2016;8(1):61–9. doi: https://doi.org/10.1177/1756287215614236

  38. Gross-Goupil M, Kwon TG, Eto M, Ye D,Miyake H, Seo SI, et al. Axitinib versus placeboas an adjuvant treatment of renal cell carcinoma:results from the phase III, randomized ATLAStrial. Annals of Oncology. 2018;29(12):2371–8.doi: https://doi.org/10.1093/annonc/mdy454

  39. Escudier B, Eisen T, Stadler WM, Szczylik C,Oudard S, Siebels M, et al. Sorafenib in AdvancedClear-Cell Renal-Cell Carcinoma. New EnglandJournal of Medicine. 2007;356(2):125–34. doi:https://doi.org/10.1056/nejmoa060655

  40. Kollmannsberger C, Soulieres D, Wong R,Scalera A, Gaspo R, Bjarnason G. Sunitinibtherapy for metastatic renal cell carcinoma:recommendations for management of sideeffects. Canadian Urological Association Journal.2007;1(2S). [accessed 25 Apr 2022] Availablefrom: https://dx.doi.org/10.5489%2Fcuaj.67

  41. Ko JJ, Xie W, Kroeger N, Lee J, Rini BI, KnoxJJ, et al. The International Metastatic RenalCell Carcinoma Database Consortium modelas a prognostic tool in patients with metastaticrenal cell carcinoma previously treated withfirst-line targeted therapy: a population-basedstudy. The Lancet Oncology. 2015;16(3):293–300. doi: https://doi.org/10.1016/S1470-2045(14)71222-7

  42. Malouf GG, Flippot R, Khayat D. TherapeuticStrategies for Patients With Metastatic RenalCell Carcinoma in Whom First-Line VascularEndothelial Growth Factor Receptor–DirectedTherapies Fail. JOP. 2016 May;12(5):412–20.doi: https://doi.org/10.1200/jop.2016.011809

  43. Graham J, Heng DYC, Brugarolas J,Vaishampayan U. Personalized Management ofAdvanced Kidney Cancer. Am Soc Clin OncolEduc Book. 2018;38:330–41. doi: https://doi.org/10.1200/edbk_201215

  44. Motzer RJ, Tannir NM, McDermott DF, ArénFrontera O, Melichar B, Choueiri TK, et al.Nivolumab plus Ipilimumab versus Sunitinib inAdvanced Renal-Cell Carcinoma. New EnglandJournal of Medicine. 2018;378(14):1277–90.doi: https://doi.org/10.1056/nejmoa1712126

  45. Rini BI, Plimack ER, Stus V, Gafanov R,Hawkins R, Nosov D, et al. Pembrolizumabplus Axitinib versus Sunitinib for AdvancedRenal-Cell Carcinoma. N Engl J Med.2019;380(12):1116–27. doi: https://doi.org/10.1056/nejmoa1816714

  46. Motzer RJ, Penkov K, Haanen J, Rini B, AlbigesL, Campbell MT, et al. Avelumab plus Axitinibversus Sunitinib for Advanced Renal-CellCarcinoma. New England Journal of Medicine.2019 Mar 21;380(12):1103–15. doi: https://doi.org/10.1056/nejmoa1816047

  47. Choueiri TK, Powles T, Burotto M, Escudier B,Bourlon MT, Zurawski B, et al. Nivolumab plusCabozantinib versus Sunitinib for AdvancedRenal-Cell Carcinoma. New England Journalof Medicine. 2021 Mar 4;384(9):829–41. doi:https://doi.org/10.1056/nejmoa2026982

  48. Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M,Powles T, et al. Lenvatinib plus Pembrolizumabor Everolimus for Advanced Renal CellCarcinoma. New England Journal of Medicine.2021;384(14):1289–300. doi: https://doi.org/10.1056/nejmoa2035716

  49. Motzer RJ, Escudier B, McDermott DF, GeorgeS, Hammers HJ, Srinivas S, et al. Nivolumabversus Everolimus in Advanced Renal-CellCarcinoma. New England Journal of Medicine.2015;373(19):1803–13. doi: https://dx.doi.org/10.1056%2FNEJMoa1510665

  50. Rini BI, Powles T, Atkins MB, Escudier B,McDermott DF, Suarez C, et al. Atezolizumabplus bevacizumab versus sunitinib in patientswith previously untreated metastatic renal cellcarcinoma (IMmotion151): a multicentre, openlabel,phase 3, randomised controlled trial. TheLancet. 2019;393(10189):2404–15. doi: https://doi.org/10.1016/S0140-6736(19)30723-8




2020     |     www.medigraphic.com